Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sets New 1-Year Low – What’s Next?

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) hit a new 52-week low during trading on Monday . The stock traded as low as $26.59 and last traded at $26.68, with a volume of 29974 shares traded. The stock had previously closed at $27.05.

Analyst Ratings Changes

LKFT has been the subject of several research analyst reports. Wall Street Zen lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday. UBS Group reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Royal Bank Of Canada upped their price target on shares of Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 24th. Raymond James Financial reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Finally, Zacks Research downgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Lakefront Biotherapeutics American Depositary Shares currently has a consensus rating of “Hold” and an average price target of $36.50.

Lakefront Biotherapeutics American Depositary Shares Stock Down 1.0%

The firm’s 50 day simple moving average is $29.73 and its 200-day simple moving average is $31.63. The company has a market capitalization of $1.76 billion, a PE ratio of -18.99 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The firm had revenue of $1.06 billion during the quarter. As a group, sell-side analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LKFT. Ameriprise Financial Inc. boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 2,490.1% in the third quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock valued at $49,083,000 after purchasing an additional 1,362,229 shares during the period. UBS Group AG boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 128.4% in the fourth quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock valued at $11,427,000 after purchasing an additional 196,445 shares during the period. Millennium Management LLC boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 121.9% in the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after purchasing an additional 186,452 shares during the period. Jane Street Group LLC boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 2,245.7% in the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after purchasing an additional 115,946 shares during the period. Finally, Kotler Kevin purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the fourth quarter valued at $2,943,000. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.